Tanabe Yasuhiro, Sato Yukio, Izumo Masaki, Ishibashi Yuki, Higuma Takumi, Harada Tomoo, Akashi Yoshihiro J
Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki-City, Kanagawa 216-8511, Japan.
J Invasive Cardiol. 2019 Feb;31(2):E44. doi: 10.25270/jic/18.00206.
The current guidelines recommend a minimum of 6 months of antithrombotic and antibiotic prophylaxis following septal occluding device placement for transcatheter closure of atrial septal defect. Full neoendothelialization is thought to be completed within 6 months of device implantation; however, there is no method available that can assess the level of neoendothelialization in vivo. This report therefore evaluates endothelialization in vivo and demonstrates that 6 months of postimplantation prophylactic therapy may not provide sufficient time for adequate endothelialization. Further investigations are warranted to determine the optimal duration of these treatments after atrial septal defect closure.
目前的指南建议,在经导管封堵房间隔缺损植入间隔封堵装置后,至少进行6个月的抗血栓和抗生素预防。人们认为完全的新内皮化在装置植入后6个月内完成;然而,目前尚无可用方法在体内评估新内皮化水平。因此,本报告评估了体内内皮化情况,并表明植入后6个月的预防性治疗可能未提供足够时间实现充分的内皮化。有必要进行进一步研究以确定房间隔缺损封堵后这些治疗的最佳持续时间。